BUZZ-U.S. STOCKS ON THE MOVE-OHR Pharma, Mavenir, Sucampo, Doral

Mon Mar 2, 2015 12:18pm EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article | Single Page
[-] Text [+]

(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter,; for the Morning News Call newsletter,

The Nasdaq Composite index hit the 5,000 mark on Monday for the first time since March 27, 2000 and edged closer to its 5,132.52 all-time peak it reached that same month in the frenzy of the dot-come bubble. The Dow Jones industrial average was up 0.51 percent at 18,225.47, the S&P 500 was up 0.27 percent at 2,110.13 and the Nasdaq Composite was up 0.52 percent at 4,989.164.

** OHR PHARMACEUTICAL INC, $10.2799, +33.68 pct

The eye drug developer said the mid-stage study of its squalamine eye drops improved vision by week 4 in patients with a wet form of age-related blindness, when used in combination with lucentis. Cowen and Co initiated coverage of the stock with an "outperform" rating and price target of $25.


The hardwood flooring retailer sold flooring with higher levels of formaldehyde than permitted under California's health and safety standards, according to television news program "60 Minutes".

Morgan Stanley downgrades stock to "equal-weight" from "overweight".